Health & Fitness
Health and Fitness
Health and Fitness
Sat, September 24, 2011Fri, September 23, 2011Thu, September 22, 2011Wed, September 21, 2011Tue, September 20, 2011Mon, September 19, 2011Sun, September 18, 2011Sat, September 17, 2011Fri, September 16, 2011Thu, September 15, 2011Wed, September 14, 2011Tue, September 13, 2011Mon, September 12, 2011Sun, September 11, 2011Sat, September 10, 2011Fri, September 9, 2011Thu, September 8, 2011Wed, September 7, 2011Tue, September 6, 2011Mon, September 5, 2011Sun, September 4, 2011Sat, September 3, 2011Fri, September 2, 2011Thu, September 1, 2011Wed, August 31, 2011Tue, August 30, 2011Mon, August 29, 2011Fri, August 26, 2011iCo Therapeutics CEO to Present &;; Act as Co-Chairperson at the 4th Annual Drug Repositioning and Pipeline Enhancement
Published on Tuesday, September 13th 2011 at 12:22 GMT by Market Wire
VANCOUVER, Sept. 13, 2011 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO) is pleased to announce that Andrew Rae, iCo's President and CEO, will present at the 4th Annual Drug Repositioning and Pipeline Enhancement Conference on September 13-14, 2011 in Philadelphia, PA. Mr. Rae's presentation will be take place at 9:45am on September 14th, 2011. Mr. Rae will also act as Chairperson of the conference on September 14th, 2011.
About iCo Therapeutics
iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011. iCo trades on the TSX Venture Exchange under the symbol "ICO". For more information, visit the Company website at: [ www.icotherapeutics.com ].
No regulatory authority has approved or disapproved the content of this release. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered forward-looking. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on iCo Therapeutics' current beliefs as well as assumptions made by and information currently available to iCo Therapeutics and relate to, among other things, anticipated financial performance, business prospects, strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by iCo Therapeutics in its public securities filings; actual events may differ materially from current expectations. iCo Therapeutics disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
